News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
594,860 Results
Type
Article (40487)
Company Profile (92)
Press Release (554275)
Multimedia
Podcasts (143)
Webinars (24)
Section
Business (175139)
Career Advice (2202)
Deals (28860)
Drug Delivery (108)
Drug Development (62240)
Employer Resources (150)
FDA (14160)
Job Trends (12697)
News (286802)
Policy (27322)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (2217)
Academic (1)
Accelerated approval (27)
Adcomms (21)
Allergies (128)
Alliances (45166)
ALS (151)
Alzheimer's disease (1439)
Antibody-drug conjugate (ADC) (258)
Approvals (14432)
Artificial intelligence (532)
Autoimmune disease (152)
Automation (40)
Bankruptcy (268)
Best Places to Work (9938)
BIOSECURE Act (15)
Biosimilars (161)
Biotechnology (66)
Bladder cancer (142)
Brain cancer (49)
Breast cancer (569)
Cancer (4267)
Cardiovascular disease (362)
Career advice (1886)
Career pathing (36)
CAR-T (239)
CDC (66)
Celiac Disease (1)
Cell therapy (663)
Cervical cancer (33)
Clinical research (52920)
Collaboration (1648)
Company closure (6)
Compensation (594)
Complete response letters (40)
COVID-19 (2791)
CRISPR (87)
C-suite (762)
Cystic fibrosis (113)
Data (5484)
Decentralized trials (2)
Denatured (44)
Depression (127)
Diabetes (434)
Diagnostics (6927)
Digital health (42)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (238)
Drug pricing (169)
Drug shortages (27)
Duchenne muscular dystrophy (198)
Earnings (77307)
Editorial (62)
Employer branding (20)
Employer resources (137)
Events (90092)
Executive appointments (864)
FDA (16883)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (8)
Frontotemporal dementia (23)
Funding (1279)
Gene editing (174)
Generative AI (51)
Gene therapy (543)
GLP-1 (840)
Government (4244)
Grass and pollen (6)
Guidances (364)
Healthcare (15581)
HIV (60)
Huntington's disease (40)
IgA nephropathy (67)
Immunology and inflammation (216)
Immuno-oncology (60)
Indications (121)
Infectious disease (3081)
Inflammatory bowel disease (162)
Inflation Reduction Act (15)
Influenza (128)
Intellectual property (200)
Interviews (401)
IPO (13147)
IRA (45)
Job creations (3091)
Job search strategy (1554)
JPM (61)
Kidney cancer (15)
Labor market (72)
Layoffs (474)
Leadership (38)
Legal (6760)
Liver cancer (75)
Longevity (16)
Lung cancer (559)
Lymphoma (327)
Machine learning (38)
Management (52)
Manufacturing (741)
MASH (153)
Medical device (10986)
Medtech (11040)
Mergers & acquisitions (16662)
Metabolic disorders (1095)
mRNA (191)
Multiple sclerosis (149)
NASH (15)
Neurodegenerative disease (298)
Neuropsychiatric disorders (77)
Neuroscience (2528)
NextGen: Class of 2026 (5273)
Non-profit (3830)
Now hiring (43)
Obesity (499)
Opinion (304)
Ovarian cancer (147)
Pain (168)
Pancreatic cancer (201)
Parkinson's disease (241)
Partnered (30)
Patents (407)
Patient recruitment (388)
Peanut (50)
People (49312)
Pharmaceutical (23)
Pharmacy benefit managers (23)
Phase 1 (16297)
Phase 2 (22779)
Phase 3 (18371)
Pipeline (5424)
Policy (288)
Postmarket research (2181)
Preclinical (6899)
Press Release (70)
Prostate cancer (253)
Psychedelics (43)
Radiopharmaceuticals (278)
Rare diseases (784)
Real estate (4904)
Recruiting (61)
Regulatory (20248)
Reports (38)
Research institute (2071)
Resumes & cover letters (340)
Rett syndrome (29)
RNA editing (16)
RSV (86)
Schizophrenia (133)
Series A (215)
Series B (159)
Service/supplier (5)
Sickle cell disease (86)
Special edition (23)
Spinal muscular atrophy (129)
Sponsored (43)
Startups (2914)
State (1)
Stomach cancer (14)
Supply chain (89)
Tariffs (78)
The Weekly (97)
Vaccines (1186)
Venture capital (79)
Weight loss (321)
Women's health (86)
Worklife (19)
Date
Today (172)
Last 7 days (598)
Last 30 days (2602)
Last 365 days (25199)
2026 (4666)
2025 (25379)
2024 (28638)
2023 (32567)
2022 (42848)
2021 (46331)
2020 (45275)
2019 (38438)
2018 (28965)
2017 (27347)
2016 (26755)
2015 (31393)
2014 (25870)
2013 (22256)
2012 (22969)
2011 (23242)
2010 (21835)
Location
Africa (852)
Alabama (80)
Alaska (6)
Arizona (241)
Arkansas (10)
Asia (34007)
Australia (5920)
California (9262)
Canada (2779)
China (874)
Colorado (428)
Connecticut (446)
Delaware (264)
Europe (81100)
Florida (1452)
Georgia (313)
Hawaii (1)
Idaho (43)
Illinois (725)
India (74)
Indiana (454)
Iowa (19)
Japan (405)
Kansas (105)
Kentucky (40)
Louisiana (21)
Maine (82)
Maryland (1187)
Massachusetts (6721)
Michigan (333)
Minnesota (481)
Mississippi (5)
Missouri (105)
Montana (31)
Nebraska (21)
Nevada (119)
New Hampshire (66)
New Jersey (2739)
New Mexico (28)
New York (2508)
North Carolina (1252)
North Dakota (9)
Northern California (4520)
Ohio (295)
Oklahoma (20)
Oregon (31)
Pennsylvania (1859)
Puerto Rico (11)
Rhode Island (38)
South America (1067)
South Carolina (48)
Southern California (3668)
Tennessee (159)
Texas (1493)
United States (33768)
Utah (318)
Vermont (1)
Virginia (235)
Washington D.C. (70)
Washington State (747)
West Virginia (4)
Wisconsin (114)
Wyoming (2)
594,860 Results for "chiron corporation now novartis vaccines and diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
February 20, 2026
·
3 min read
Artificial intelligence
AI Is Changing Pharma’s Bottom Line Now—But Not Through Splashy Drug Discovery
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
February 11, 2026
·
8 min read
·
Annalee Armstrong
Pipeline
Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy
Despite the Phase 1 cull, CEO Vas Narasimhan on Wednesday maintained that Novartis continues to invest in its early-stage pipeline, looking for deals in the “sub-$2-billion range.”
February 5, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Novartis Names Texas City as Location of Its 5th US Radiopharmaceutical Facility
The Denton site is part of a network of manufacturing plants Novartis is building across the U.S. to make cancer drugs that must be shipped to patients quickly.
February 25, 2026
·
2 min read
·
Nick Paul Taylor
Collaboration
Novartis Bets Up to $1.7B in Cardio-Focused Peptide Partnership
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
February 19, 2026
·
2 min read
·
Tristan Manalac
Vaccines
Flu Vaccine Rejection Imperils Moderna’s Breakeven Plans
Moderna’s mRNA-1010 was expected to contribute $1 billion to the company’s coffers by 2028. That plan is now out the window after the FDA refused to even look at the application.
February 12, 2026
·
4 min read
·
Dan Samorodnitsky
Earnings
Novartis Sticks With M&A Strategy of Building Early Pipeline, Searching for Near-Launches
Novartis will still be on the lookout for early-stage deals under $2 billion, and later-stage agreements around a product that could reach the market within five years, CEO Vas Narasimhan said Wednesday.
February 4, 2026
·
2 min read
·
Tristan Manalac
obesity
JPM26: Novartis Doesn’t Have a GLP-1. They Don’t Miss It In a World Of Me-Toos
Speaking to
BioSpace
at the J.P. Morgan Healthcare Conference, Novartis’ chief dealmaker Ronny Gal explains why the Swiss pharma hasn’t acquired a GLP-1, and why it probably won’t.
January 13, 2026
·
3 min read
·
Annalee Armstrong
Career Advice
The Top 12 Companies Hiring in Biopharma Now
Looking for a biopharma job? Check out the
BioSpace
list of 12 top companies hiring life sciences professionals like you.
March 5, 2026
·
1 min read
·
Angela Gabriel
Radiopharmaceuticals
Novartis’ Pluvicto Heavywork Proves Radiopharma Can Succeed
While investment has slowed in radiopharmaceuticals, analysts predict increased interest to come as Novartis shows just how successful radiopharmaceuticals can be.
November 6, 2025
·
5 min read
·
Annalee Armstrong
1 of 59,486
Next
